Shanghai Kindly Medical Instruments (1501) has a market capitalization of approximately HK$5.8B, trading at HK
Shanghai Kindly Medical Instruments's trailing twelve-month P/E ratio is 25.3x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Shanghai Kindly Medical Instruments runs a net profit margin of 20.5%, a gross margin of 59.8%, and an operating margin of 25.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Shanghai Kindly Medical Instruments reported revenue of ¥1.1B for fiscal year 2025, with net income of ¥219M and earnings per share (EPS) of 1.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Shanghai Kindly Medical Instruments offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Shanghai Kindly Medical Instruments carries a debt-to-equity ratio of 0.36x and a current ratio of 1.26x, with a market beta of 0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Kindly Medical Instruments (1501) the key facts are: market cap HK$5.8B, P/E 25.3x, revenue ¥1.1B, 52-week range 22.7-41.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get Shanghai Kindly Medical Instruments's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.